Drug Profile
Research programme: antimicrobial resistance therapeutics - Aceragen
Alternative Names: ARV-1501; ARV-1503X; ARV-1601; Designer Proline-rich Antimicrobial Peptide Chaperone-protein Inhibitors - AceragenLatest Information Update: 05 Oct 2022
Price :
$50
*
At a glance
- Originator Arrevus
- Developer Aceragen
- Class Anti-infectives; Antibacterials; Peptides
- Mechanism of Action Bacterial protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Sep 2022 Aceragen has been acquired by Idera Pharmaceuticals
- 28 Apr 2022 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 05 Dec 2018 Arrevus receives STTR grant from the National Institute of Allergy and Infectious Diseases to develop DnaK inhibitor platform for Antibiotic resistant infections